Peter Ferdinandy



  1. Gomes C, Agg B, Andova A, Arslan S, Baker A, Barteková M, et al. Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129. Noncoding RNA. 2019;5: pubmed publisher
    ..COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks ( ..
  2. Lázár B, Brenner G, Makkos A, Balogh M, László S, Al Khrasani M, et al. Lack of Small Intestinal Dysbiosis Following Long-Term Selective Inhibition of Cyclooxygenase-2 by Rofecoxib in the Rat. Cells. 2019;8: pubmed publisher
    ..Moreover, inhibition of COX-2 activity is not likely to be responsible per se for microbial alterations caused by some coxibs, but other drug-specific properties may contribute to it. ..
  3. Bencsik P, Kiss K, Agg B, Baán J, Agoston G, Varga A, et al. Sensory Neuropathy Affects Cardiac miRNA Expression Network Targeting IGF-1, SLC2a-12, EIF-4e, and ULK-2 mRNAs. Int J Mol Sci. 2019;20: pubmed publisher
    ..These results further support the need for unbiased omics approach followed by in silico prediction and validation of molecular targets to reveal novel pathomechanisms. ..
  4. Madonna R, Balistreri C, De Rosa S, Muscoli S, Selvaggio S, Selvaggio G, et al. Impact of Sex Differences and Diabetes on Coronary Atherosclerosis and Ischemic Heart Disease. J Clin Med. 2019;8: pubmed publisher
    ..We analyze whether sex may modify the effects of diabetes at risk of CAD. Finally, we discuss current diagnostic techniques in the evaluation of CAD and IHD in diabetic women. ..
  5. Poz D, De Falco E, Pisano C, Madonna R, Ferdinandy P, Balistreri C. Diagnostic and prognostic relevance of Red blood cell distribution width for vascular aging and cardiovascular diseases. Rejuvenation Res. 2018;: pubmed publisher
  6. Madonna R, Cadeddu C, Deidda M, Giricz Z, Madeddu C, Mele D, et al. Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology. Int J Cardiol. 2015;191:203-10 pubmed publisher
    ..We discuss signaling pathways associated with cardioprotection that can be targeted by gene therapy to achieve cardioprotection. ..
  7. Agg B, Baranyai T, Makkos A, Vető B, Faragó N, Zvara A, et al. MicroRNA interactome analysis predicts post-transcriptional regulation of ADRB2 and PPP3R1 in the hypercholesterolemic myocardium. Sci Rep. 2018;8:10134 pubmed publisher
  8. Sárközy M, Szűcs G, Pipicz M, Zvara Ã, Éder K, Fekete V, et al. The effect of a preparation of minerals, vitamins and trace elements on the cardiac gene expression pattern in male diabetic rats. Cardiovasc Diabetol. 2015;14:85 pubmed publisher
    ..Our results and further studies exploring the mechanistic role of individual genes may contribute to the prevention or diagnosis of cardiac complications in diabetes. ..
  9. Bencsik P, Pálóczi J, Kocsis G, Pipis J, Belecz I, Varga Z, et al. Moderate inhibition of myocardial matrix metalloproteinase-2 by ilomastat is cardioprotective. Pharmacol Res. 2014;80:36-42 pubmed publisher
    ..Furthermore, this is the first demonstration that a moderate inhibition of intracellular MMP-2 is sufficient to confer cardiocytoprotection. ..

More Information


  1. request reprint
    Varga Z, Giricz Z, Bencsik P, Madonna R, Gyongyosi M, Schulz R, et al. Functional Genomics of Cardioprotection by Ischemic Conditioning and the Influence of Comorbid Conditions: Implications in Target Identification. Curr Drug Targets. 2015;16:904-11 pubmed
    ..Further understanding and the comprehensive analysis of the cardioprotective gene expression fingerprint in normal, protected, and in comorbid conditions may lead to identification of novel molecular targets for cardioprotection. ..
  2. Varga Z, Agg B, Ferdinandy P. miR-125b is a protectomiR: A rising star for acute cardioprotection. J Mol Cell Cardiol. 2017;: pubmed publisher
    ..Micro-RNAs are promising novel targets for cardioprotection as highlighted by recent seminal position papers and reviews (Hausenloy et al., 2017; Varga et al., 2015; Perrino et al., 2017 [1-3]). ..
  3. Koncsos G, Varga Z, Baranyai T, Ferdinandy P, Schulz R, Giricz Z, et al. Nagarse treatment of cardiac subsarcolemmal and interfibrillar mitochondria leads to artefacts in mitochondrial protein quantification. J Pharmacol Toxicol Methods. 2018;91:50-58 pubmed publisher
    ..Therefore, protease sensitivity should be considered when assessing distribution of mitochondrial proteins using nagarse-based isolation. ..
  4. Baranyai T, Nagy C, Koncsos G, Onódi Z, Károlyi Szabó M, Makkos A, et al. Acute hyperglycemia abolishes cardioprotection by remote ischemic perconditioning. Cardiovasc Diabetol. 2015;14:151 pubmed publisher
    ..The mechanism of this phenomenon may involve an acute hyperglycemia-induced increase in nitrative stress and activation of the mTOR pathway. ..
  5. Sárközy M, Fekete V, Szűcs G, Török S, Szűcs C, Bárkányi J, et al. Anti-diabetic effect of a preparation of vitamins, minerals and trace elements in diabetic rats: a gender difference. BMC Endocr Disord. 2014;14:72 pubmed publisher
    ..Moreover, we have confirmed that females are less sensitive to STZ-induced diabetes and MVT preparation did not show protection against prediabetic state. This may suggest a gender difference in the pathogenesis of diabetes. ..
  6. Baranyai T, Giricz Z, Varga Z, Koncsos G, Lukovic D, Makkos A, et al. In vivo MRI and ex vivo histological assessment of the cardioprotection induced by ischemic preconditioning, postconditioning and remote conditioning in a closed-chest porcine model of reperfused acute myocardial infarction: importance of microvascul. J Transl Med. 2017;15:67 pubmed publisher
    ..We conclude that IPostC and RIC interventions may protect the coronary microvasculature even without reducing myocardial necrosis. ..
  7. Kemeny A, Csekő K, Szitter I, Varga Z, Bencsik P, Kiss K, et al. Integrative characterization of chronic cigarette smoke-induced cardiopulmonary comorbidities in a mouse model. Environ Pollut. 2017;229:746-759 pubmed publisher
  8. Kiss K, Csonka C, Pálóczi J, Pipis J, Gorbe A, Kocsis G, et al. Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats. Pharmacol Res. 2016;113:62-70 pubmed publisher
    ..Therefore, non-erythropoietic EPO receptor peptide ligands may be promising cardioprotective agents. ..
  9. Ferdinandy P, Hausenloy D, Heusch G, Baxter G, Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev. 2014;66:1142-74 pubmed publisher
    ..This will hopefully maximize the success rate of developing rational approaches to effective cardioprotective therapies for the majority of patients with multiple risk factors. ..
  10. Bencsik P, Kupai K, Giricz Z, Gorbe A, Pipis J, Murlasits Z, et al. Role of iNOS and peroxynitrite-matrix metalloproteinase-2 signaling in myocardial late preconditioning in rats. Am J Physiol Heart Circ Physiol. 2010;299:H512-8 pubmed publisher
    ..Furthermore, increased expression of iNOS may play a role in the development of late PC; however, increased iNOS activity does not lead to increased NO production in late PC. ..
  11. Pipicz M, Kocsis G, Sárváry Arantes L, Bencsik P, Varga Z, Ferdinandy P, et al. Low-Dose Endotoxin Induces Late Preconditioning, Increases Peroxynitrite Formation, and Activates STAT3 in the Rat Heart. Molecules. 2017;22: pubmed publisher
    ..We conclude that LPS pretreatment enhances cardiac peroxynitrite formation and activates STAT3 24 h later, which may contribute to LPS-induced late preconditioning. ..